• Explore /
  • Poster
  • / Efficacy and safety comparison between belotecan and topotecan in patients with recurrent or refractory ovarian cancer: A multi-center, randomized, open-labelled, parallel-group phase IIb trial.

Efficacy and safety comparison between belotecan and topotecan in patients with recurrent or refractory ovarian cancer: A multi-center, randomized, open-labelled, parallel-group phase IIb trial.

Abstract Poster

Authors

null

Hee Seung Kim

Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea

Hee Seung Kim , Sang-Yoon Park , Chan-Yong Park , Young-Tae Kim , Beob-Jong Kim , Yong Jung Song , Byoung Gie Kim , Yong Beom Kim , Chi-Heum Cho , Jong-Hyeok Kim , Yong Sang Song

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT01630018

Citation

J Clin Oncol 33, 2015 (suppl; abstr 5527)

DOI

10.1200/jco.2015.33.15_suppl.5527

Abstract #

5527

Poster Bd #

85

Abstract Disclosures

Similar Posters

First Author: Man Jiang

First Author: Isabelle Laure Ray-Coquard

First Author: Julien Taieb

First Author: Nieves Martinez Lago